<DOC>
	<DOCNO>NCT00016081</DOCNO>
	<brief_summary>RATIONALE : Antivirals ribavirin use treat infection cause virus . It yet know ribavirin effective standard therapy prevent pneumonia patient respiratory syncytial virus ( RSV ) infection follow stem cell transplantation . PURPOSE : Randomized phase III trial compare effectiveness ribavirin standard therapy prevent pneumonia patient RSV infection follow stem cell transplantation .</brief_summary>
	<brief_title>Ribavirin Compared With Standard Care Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy aerosolize ribavirin vs standard supportive therapy , term prevent progression upper respiratory tract respiratory syncytial virus ( RSV ) infection pneumonia , patient RSV follow stem cell transplantation . - Determine safety aerosolize ribavirin patient population . OUTLINE : This randomize , investigator-blind , control , multicenter study . Patients stratify accord engraftment status ( pre v post ) transplant type ( HLA matched-related allogeneic , syngeneic , autologous v HLA mismatched-related unrelated allogeneic ) . Patients randomize one two treatment arm . - Arm I : Patients receive standard supportive care immunocompromised patient upper respiratory tract infection . Patient also receive aerosolize ribavirin face mask , mist , oxygen tent 2 hour 3 time daily day 1-10 . - Arm II : Patients receive standard supportive care arm I . Treatment continue absence progression pneumonia unacceptable toxicity . Patients follow day 14 28 . PROJECTED ACCRUAL : A total 90 patient ( 45 per arm ) accrue study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed upper respiratory tract respiratory syncytial virus ( RSV ) infection document nasopharyngealthroat specimen rapid antigen test ( ELISA ) , IFA , shell vial ) Signs symptom upper respiratory tract infection ( e.g. , rhinorrhea and/or lowgrade fever ( 101 degree F without evidence sore throat ) Received prior stem cell transplantation ( SCT ) meet one follow criterion : Between start conditioning ( preparative ) regimen day 90 allogeneic , autologous , syngeneic SCT Between day 91 180 unrelated HLA mismatchrelated allogeneic SCT Between day 91 180 SCT graftversushost disease require systemic steroid expect continue throughout study No radiographic evidence pneumonia PATIENT CHARACTERISTICS : Age : 2 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Pulmonary : Oxygen saturation 92100 % pulse oximeter Normal respiratory rate age Other : No prior adverse reaction ribavirin No clinical status would preclude study HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior immunotherapy RSV No prior concurrent RSV hyperimmune globulin monoclonal antibody Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics Radiotherapy : Not specify Surgery : Not specify Other : No prior antiviral drug antiRSV activity Bronchodilator treatment allow patient asthma history reactive airway disease and/or develop bronchospasm Concurrent ganciclovir , foscarnet , IV immunoglobulin allow No mechanical ventilation No concurrent antiviral drug antiRSV activity</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>infection</keyword>
</DOC>